Compare Gitlab Inc (GTLB) vs Immunovant Inc. Common Stock (IMVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Immunovant Inc. Common Stock — how do they compare? Gitlab Inc trades at $53.52 (market cap $8.66B), while Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B). The key difference: Gitlab Inc is the larger of the two by market cap, and Gitlab Inc is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Immunovant Inc. Common Stock for 0 Days on average.
| GTLB | IMVT | |
|---|---|---|
Market Cap | $8.66B | $6.62B |
Volume | 2,403,535 | 1,131,364 |
Sector | Technology | Health |
52-Week High | $53.56 | $44.96 |
52-Week Low | $19.42 | $17.03 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $7.40B | $5.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $53.56, up 3.74% today and near its 52-week high, with strong technical momentum. The company shows accelerating revenue growth (21.3% YoY in Q2 2026) and consistent earnings beats, though profitability remains negative. Recent AI product traction and raised guidance have fueled investor optimism, with the stock gaining 35% in August 2026 alone.
Outlook is mixed: strong sales momentum and AI integration offer upside, but high valuation (P/E 521) and negative margins pose risks. Analyst consensus is cautious (36.7% Buy, 60% Hold) with a $49.71 price target below current levels, suggesting limited near-term upside despite positive business trends.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →
